drugset / Trial / NCT03111901
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety and disease control rate of the combination of pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or renal cell cancer.
Timeline
- Start
- 2018-10-29
- Primary completion
- 2023-10
- Completion
- 2023-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 5 unknown | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 12 unknown | Subcutaneous |